Latest Ratios: P/E Ratio -11.1x · EV/EBITDA N/A · ROE -63.5%. (2000–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.3B | $608M | $776M | $237M | $166M | $68M | $179M | $252M | $260M | — |
| Enterprise Value | $1.2B | $1.3B | $620M | $776M | $211M | $158M | $71M | $155M | $252M | $253M | — |
| P/E Ratio → | -11.13 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 265.39 | — | — | — | — |
| P/B Ratio | 6.46 | 6.60 | 3.55 | 5.53 | 2.20 | 1.15 | 1.06 | 1.76 | 2.33 | 2.18 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 274.74 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -13533.5% | — | — | — | 100.0% |
| Operating Margin | — | — | — | — | — | — | -19182.9% | — | — | — | -2737.0% |
| Net Profit Margin | — | — | — | — | — | — | -19305.4% | — | — | — | -2730.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.5% | -63.5% | -61.5% | -44.1% | -30.2% | -41.2% | -59.7% | -74.5% | -54.1% | -71.4% | — |
| ROA | -51.0% | -51.0% | -49.1% | -34.5% | -24.1% | -31.4% | -42.4% | -54.2% | -39.4% | -31.6% | -26.3% |
| ROIC | -48.4% | -48.4% | -47.9% | -40.5% | -26.7% | -30.6% | -51.3% | -63.8% | -47.5% | -66.3% | — |
| ROCE | -57.3% | -57.3% | -56.5% | -39.9% | -26.3% | -33.0% | -45.9% | -58.5% | -46.9% | -33.5% | -38.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.15 | 0.15 | 0.16 | 0.19 | 0.24 | 0.18 | 0.39 | 0.25 | 0.23 | 0.13 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.02 | 0.07 | -0.00 | -0.24 | -0.06 | 0.04 | -0.24 | 0.00 | -0.06 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -432.31 | -17.81 | -31.11 | -724.87 | -6366.09 | -27.80 | -23.14 |
Net cash position: cash ($33M) exceeds total debt ($30M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.85 | 11.85 | 13.73 | 15.66 | 21.98 | 11.26 | 10.41 | 11.40 | 15.63 | 16.27 | 4.23 |
| Quick Ratio | 11.85 | 11.85 | 13.73 | 15.66 | 21.63 | 11.33 | 10.41 | 11.55 | 15.63 | 15.86 | 4.13 |
| Cash Ratio | 11.56 | 11.56 | 13.33 | 15.32 | 21.45 | 10.99 | 10.05 | 11.19 | 15.28 | 15.68 | 3.87 |
| Asset Turnover | — | — | — | — | — | — | 0.00 | — | — | — | 0.01 |
| Inventory Turnover | — | — | — | — | 13.58 | — | — | — | — | 0.15 | — |
| Days Sales Outstanding | — | — | — | — | — | — | 2407.30 | — | — | — | 792.05 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.4% | 0.4% | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.4% | 0.4% | 0.2% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $222M | $198M | $165M | $153M | $134M | $59M | $40M | $33M | $18M | $3M |
Binary clinical trial outcome
According to recent market data, Savara trades at a price-to-book ratio of 6.46, which appears elevated relative to the company's pre-revenue status and reflects investor anticipation of the IMPALA-2 trial results rather than any fundamental earnings-based valuation metrics currently supported by the firm's financial statements.
The absence of P/E or EV/EBITDA multiples underscores that the market is pricing the company as a binary option on its lead asset rather than a traditional operating business. Investors should monitor whether this premium valuation can be sustained if clinical data fails to meet the high expectations currently baked into the share price.
Based on reported figures, Savara's ROIC has consistently remained in negative territory, deteriorating to -15.9% in 2026Q1, which highlights the company's ongoing struggle to generate positive returns on invested capital while it remains entirely dependent on external equity funding to sustain its clinical development pipeline.
The persistent negative ROIC is a structural feature of the company's current lifecycle stage, where capital is deployed into non-revenue-generating R&D rather than productive assets. This trend suggests that shareholders should expect continued value dilution until the company can demonstrate a clear path to commercialization and positive operating margins.
As reported in recent financial statements, the company's current ratio has declined from 15.66 in 2023Q4 to 13.47 in 2026Q1, indicating that while the firm maintains a high liquidity buffer, the rapid depletion of cash reserves warrants close monitoring as the company approaches its critical data readout.
The high current ratio is somewhat misleading as it reflects the immediate availability of cash raised through prior equity offerings rather than operational efficiency. Given the high burn rate, this liquidity position may prove insufficient to fund commercial launch preparations without further dilutive financing, regardless of the clinical outcome.
Investors frequently misapply the current ratio to evaluate Savara's financial health, yet this metric obscures the reality that the company's cash is not a product of operations but a finite pool of capital that is being systematically exhausted to fund the IMPALA-2 clinical trial.
A more appropriate metric for this business model is the 'burn-to-milestone' ratio, which measures the remaining cash runway against the time required to reach the next major regulatory or clinical catalyst. Relying on standard liquidity ratios may lead to an underestimation of the imminent financing risk inherent in the company's current capital structure.
Includes 30+ ratios · 26 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SVRA stock.
Savara Inc.'s current P/E ratio is -11.1x. This places it at the 50th percentile of its historical range.
Savara Inc.'s return on equity (ROE) is -63.5%. The historical average is -95.2%.
Based on historical data, Savara Inc. is trading at a P/E of -11.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.